trending Market Intelligence /marketintelligence/en/news-insights/trending/nX_24498_lIqHG7h7bqzuA2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Momenta Pharmaceuticals to raise up to $230M from common stock offering

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform

Momenta Pharmaceuticals to raise up to $230M from common stock offering

Momenta Pharmaceuticals Inc. priced an underwritten public offering of its common stock to raise up to $230 million in gross proceeds.

The Cambridge, Mass.-based biotechnology company is offering $200 million worth of its shares. Underwriters will also receive an option to buy up to an additional $30 million of the company's common stock.

Goldman Sachs & Co. LLC and J.P. Morgan are acting as joint lead book-running managers for the offering, while Stifel is acting as a book-running manager.